Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells $1,003,400.00 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $50.17, for a total value of $1,003,400.00. Following the completion of the sale, the chief executive officer now owns 2,243,985 shares of the company’s stock, valued at $112,580,727.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ultragenyx Pharmaceutical Trading Down 0.5 %

Shares of NASDAQ RARE opened at $50.03 on Friday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $31.52 and a 52 week high of $54.56. The business’s 50 day moving average price is $43.03 and its 200 day moving average price is $44.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.64) by $0.12. The firm had revenue of $147.03 million during the quarter, compared to analysts’ expectations of $123.20 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The firm’s revenue was up 35.7% compared to the same quarter last year. During the same quarter last year, the company posted ($2.25) earnings per share. On average, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Cantor Fitzgerald lifted their price target on shares of Ultragenyx Pharmaceutical from $115.00 to $116.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. The Goldman Sachs Group raised their price objective on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Royal Bank of Canada assumed coverage on Ultragenyx Pharmaceutical in a research report on Monday, April 22nd. They set an “outperform” rating and a $77.00 price target on the stock. Stifel Nicolaus upped their price objective on shares of Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the stock a “buy” rating in a research note on Friday, May 31st. Finally, TD Cowen boosted their price target on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $87.43.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several institutional investors have recently made changes to their positions in RARE. Massachusetts Financial Services Co. MA lifted its position in shares of Ultragenyx Pharmaceutical by 38.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 370,247 shares of the biopharmaceutical company’s stock valued at $15,217,000 after buying an additional 103,280 shares in the last quarter. Angeles Investment Advisors LLC increased its position in shares of Ultragenyx Pharmaceutical by 49.3% during the second quarter. Angeles Investment Advisors LLC now owns 6,640 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 2,193 shares in the last quarter. Federated Hermes Inc. raised its stake in Ultragenyx Pharmaceutical by 8.7% in the 2nd quarter. Federated Hermes Inc. now owns 2,107,025 shares of the biopharmaceutical company’s stock valued at $86,599,000 after purchasing an additional 168,345 shares during the last quarter. BOKF NA boosted its stake in Ultragenyx Pharmaceutical by 23.5% during the 2nd quarter. BOKF NA now owns 8,316 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 1,580 shares during the last quarter. Finally, Headlands Technologies LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 931.0% during the second quarter. Headlands Technologies LLC now owns 6,124 shares of the biopharmaceutical company’s stock worth $252,000 after buying an additional 5,530 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.